Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Medications For Heart Failure Industry Expected To Reach By 2029, Starting From 2025 Levels?
The market size for medications addressing heart failure has experienced significant growth in recent years. It is anticipated to expand from $10.14 billion in 2024 to $10.79 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.4%. The expansion observed historically can be attributed to the increasing incidence of cardiovascular diseases, improved diagnosis and public awareness, regulatory support and approvals, augmented research and development expenditure on cardiovascular drugs, and the integration of telemedicine and remote monitoring technologies.
The market for medications treating heart failure is projected to experience robust expansion in the upcoming years, with its size expected to reach $14.07 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.8%. This anticipated growth throughout the forecast period can be attributed to several factors, including the progression of personalized and precision medicine, the escalating global prevalence of lifestyle diseases, the development of combination therapies and fixed-dose formulations, growing clinical evidence coupled with updated guidelines, and increasing urbanization. Prominent trends shaping the market during this period include the rising adoption of SGLT2 inhibitors, enhanced digital health integration, the deployment of remote monitoring tools and AI-driven analytics, a sharpened focus on treatment for heart failure with preserved ejection fraction (HFpEF), and continuous research and development initiatives.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24315&type=smp
What Are The Main Drivers Boosting The Medications For Heart Failure Industry’s Expansion?
The growing incidence of cardiovascular diseases is anticipated to boost the expansion of the medications for the heart failure market moving ahead. These diseases are conditions affecting the heart and blood vessels, frequently leading to serious complications like heart attacks and strokes. A major contributor to the increase in cardiovascular diseases is inactive lifestyles, which gradually compromise cardiac and vascular health. With an uptick in cardiovascular disease rates, the need for effective therapies escalates, encouraging increased investment in heart failure medications. As this condition becomes more prevalent, pharmaceutical firms are emphasizing the creation and improvement of treatments to more effectively manage symptoms and enhance patient results. For example, in September 2024, data from the Heart Failure Society of America (HFSA), a US-based organization of heart failure experts, indicated that approximately 6.7 million Americans aged 20 and older are currently living with heart failure (HF). This figure is anticipated to climb to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Consequently, the expanding occurrence of cardiovascular diseases is fueling the expansion of medications for the heart failure market.
What Are The Major Segment Categories Driving The Medications For Heart Failure Market Growth?
The medications for heart failuremarket covered in this report is segmented –
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors; Beta Blockers; Diuretics; Aldosterone Antagonists; Angiotensin II Receptor Blockers (ARBs); Other Drug Classes
2) By Route Of Administration: Oral; Intravenous; Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
4) By Application: Hospital; Clinic; Other Applications
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril; Lisinopril; Ramipril; Captopril; Perindopril; Other Angiotensin-Converting Enzyme (ACE) Inhibitors
2) By Beta Blockers: Carvedilol; Metoprolol Succinate; Bisoprolol; Nebivolol; Other Beta Blockers
3) By Diuretics: Loop Diuretics; Thiazide Diuretics; Potassium-Sparing Diuretics; Other Diuretics
4) By Aldosterone Antagonists: Spironolactone; Eplerenone; Other Aldosterone Antagonists
5) By Angiotensin II Receptor Blockers (ARBs): Valsartan; Losartan; Candesartan; Irbesartan; Other Angiotensin II Receptor Blockers (ARBs)
6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors; Ivabradine; Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors; Hydralazine Or Isosorbide Dinitrate; Digoxin; Other Medications
How Are Emerging Market Trends Shaping The Medications For Heart Failure Industry Landscape?
Major companies operating in the medication for heart failure market are concentrating on the development of advanced drugs, including sodium-glucose cotransporter (SGLT) inhibitors, to offer more effective long-term management of heart failure symptoms and associated complications. An SGLT inhibitor represents an advanced medication specifically designed to target glucose reabsorption mechanisms to assist in managing heart failure, improving its effectiveness, and enhancing overall cardiovascular health. For example, in May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical company, introduced Inpefa (sotagliflozin), which received approval from the Food and Drug Administration (FDA). This once-daily oral tablet is formulated to diminish the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits among adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval signifies a substantial milestone for Lexicon, as Inpefa is recognized as the first dual SGLT1/SGLT2 inhibitor to become available on the market, thereby providing a novel treatment option for heart failure patients encompassing a broad range of conditions.
Which Leading Players Are Enhancing Their Medications For Heart Failure Market Presence Worldwide?
Major companies operating in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., Steris Pharma, CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Hainan Poly Pharm. Co. Ltd., Addii Biotech, Lunan Pharmaceutical Group, Mylan Laboratories Inc., Neuracle Lifesciences Private Limited, JM Laboratories, Lexicon Pharmaceuticals.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/medications-for-heart-failure-global-market-report
Which Regional Markets Are Contributing Most To The Medications For Heart Failure Industry Expansion?
North America was the largest region in the medications for the heart failure market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medications for heart failure market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Medications For Heart Failure Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24315&type=smp
Browse Through More Reports Similar to the Global Medications For Heart Failure Market 2025, By The Business Research Company
Prosthetic Heart Valve Devices And Equipment Global Market Report 2025
Flea Tick And Heartworm Products Global Market Report 2025
Implantable Heart Pacemaker Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/implantable-heart-pacemaker-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model